dexmedetomidine hydrochloride in 0.9% sodium chloride
DEXMEDETOMIDINE HYDROCHLORIDE (dexmedetomidine hydrochloride in 0.9% sodium chloride) by Eugia Pharma is 2 -adrenergic agonist with sedative properties. First approved in 2020.
Drug data last refreshed 13h ago
2 -adrenergic agonist with sedative properties. Alpha 2 selectivity is observed in animals following slow intravenous infusion of low and medium doses (10 to 300 mcg/kg). Both alpha 1 and alpha 2 activity is observed following slow intravenous infusion of high doses (≥1,000 mcg/kg) or with rapid…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study
Worked on DEXMEDETOMIDINE HYDROCHLORIDE at Eugia Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.